Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations.

Clinical and Experimental Immunology
L M PatriasDavid A Loeffler

Abstract

Alpha-synuclein is the major protein in Lewy bodies, the hallmark pathological finding in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Although normally intracellular, it also can be secreted, so extracellular alpha-synuclein may contribute to neuronal injury. Serum antibodies to alpha-synuclein could exert protective effects by increasing alpha-synuclein's movement out of the brain and, if they cross the blood-brain barrier, by inhibiting its neurotoxic effects. The objective of this study was to measure antibody concentrations to alpha-synuclein monomer and soluble oligomers in three intravenous immunoglobulin (IVIG) preparations, Gamunex (Talecris Biotherapeutics), Gammagard (Baxter Healthcare) and Flebogamma (Grifols Biologicals). Antibodies were measured in native IVIG preparations and after antibody-antigen complex dissociation. IVIG's non-specific binding was subtracted from its total binding to alpha-synuclein to calculate specific anti-alpha-synuclein antibody concentrations. Specific antibodies to alpha-synuclein monomer and/or soluble oligomers were detected in all IVIG products. In native IVIG preparations, the highest anti-monomer concentrations were in Gammagard and the highest anti-oligomer conce...Continue Reading

References

Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·K UédaT Saitoh
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Sep 24, 1999·Journal of Neuroscience Research·D F Clayton, J M George
Jul 5, 2001·Proceedings of the National Academy of Sciences of the United States of America·R B DeMattosD M Holtzman
Mar 15, 2002·The Journal of Biological Chemistry·Hirotomo MiakeMasato Hasegawa
Oct 2, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Omar M A El-AgnafDavid Allsop
Nov 1, 2003·Science·A B SingletonK Gwinn-Hardy
Mar 10, 2004·Biochemistry·Sharareh EmadiMichael R Sierks
Jun 8, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Omar M A El-AgnafDavid Allsop
Sep 21, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·R C DodelW H Oertel
Sep 29, 2004·Lancet·Marie-Christine Chartier-HarlinAlain Destée
Mar 26, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Wei ZhangJing Zhang
Jul 9, 2005·Current Opinion in Neurology·Thomas Gasser
Oct 3, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Andis KlegerisPatrick L McGeer
Mar 23, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Magali PeriquetMel B Feany
Apr 24, 2007·Journal of Neurochemistry·Katerina K PapachroniVladimir L Buchman
Dec 25, 2007·Journal of Molecular Neuroscience : MN·Seung-Jae Lee
Jan 22, 2008·The Journal of Allergy and Clinical Immunology·Duncan Lejtenyi, Bruce Mazer
Feb 26, 2008·Neurobiology of Aging·Norman R RelkinMarc E Weksler
Nov 11, 2008·Current Medicinal Chemistry·Katrin Beyer, Aurelio Ariza
May 16, 2009·Internal Medicine·Kazunori NanriKiyoshi Koizumi

❮ Previous
Next ❯

Citations

Jun 6, 2013·Journal of Neuroinflammation·David A Loeffler
Sep 28, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Eun-Jin BaeSeung-Jae Lee
Jun 15, 2014·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·Jose-Alberto Palma, Horacio Kaufmann
May 15, 2013·International Immunopharmacology·Lynnae M SmithDavid A Loeffler
Oct 3, 2012·International Immunopharmacology·Lynnae M SmithDavid A Loeffler
Jan 1, 2011·Journal of Central Nervous System Disease·Rakez KayedAlan D T Barrett
Mar 8, 2020·BMC Complementary Medicine and Therapies·Mustafa T ArdahOmar M A El-Agnaf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.